TN2009000510A1 - Extended release formulation of nevirapine - Google Patents

Extended release formulation of nevirapine

Info

Publication number: TN2009000510A1
Authority: TN; Tunisia
Prior art keywords: nevirapine; extended release; release formulation; pharmaceutical composition; relates
Prior art date: 2007-06-08

Application number

TNP2009000510A

Other languages

English (en)

Inventor

Michael L Cappolla

Sveltana Sienkiewicz

Glenn Charles Snow

Feng-Jing Chen

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-08

Filing date

2009-12-04

Publication date

2011-03-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000510(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-04 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2011-03-31 Publication of TN2009000510A1 publication Critical patent/TN2009000510A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Virology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TNP2009000510A 2007-06-08 2009-12-04 Extended release formulation of nevirapine TN2009000510A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94276507P	2007-06-08	2007-06-08
PCT/US2008/065705 WO2008154234A2 (fr)	2007-06-08	2008-06-04	Formulation à libération prolongée de névirapine

Publications (1)

Publication Number	Publication Date
TN2009000510A1 true TN2009000510A1 (en)	2011-03-31

Family

ID=39739795

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000510A TN2009000510A1 (en)	2007-06-08	2009-12-04	Extended release formulation of nevirapine

Country Status (28)

Country	Link
US (1)	US8460704B2 (fr)
EP (1)	EP2155169B1 (fr)
JP (1)	JP5417662B2 (fr)
KR (1)	KR101017862B1 (fr)
CN (1)	CN101784263B (fr)
AR (1)	AR066924A1 (fr)
AU (1)	AU2008262031B2 (fr)
BR (1)	BRPI0811732A2 (fr)
CA (1)	CA2687491C (fr)
CL (1)	CL2008001678A1 (fr)
CO (1)	CO6150128A2 (fr)
DK (1)	DK2155169T3 (fr)
EA (1)	EA018377B1 (fr)
EC (1)	ECSP099561A (fr)
ES (1)	ES2574836T3 (fr)
HU (1)	HUE028598T2 (fr)
IL (1)	IL199924A0 (fr)
MA (1)	MA31430B1 (fr)
MX (1)	MX2009007764A (fr)
NZ (1)	NZ578664A (fr)
PE (2)	PE20090371A1 (fr)
PL (1)	PL2155169T3 (fr)
TN (1)	TN2009000510A1 (fr)
TW (1)	TWI419716B (fr)
UA (1)	UA97971C2 (fr)
UY (1)	UY31128A1 (fr)
WO (1)	WO2008154234A2 (fr)
ZA (1)	ZA200904939B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en)	2008-06-27	2012-05-15	Duke University	Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
ES2574836T3 (es)	2007-06-08	2016-06-22	Boehringer Ingelheim International Gmbh	Formulación de liberación prolongada de nevirapina
US20140193491A1 (en)	2011-05-30	2014-07-10	Cipla Limited	Pharmaceutical antiretroviral composition
EP4295858A1 (fr) *	2011-08-24	2023-12-27	ImmunoForge Co., Ltd.	Formulations des principes actifs destinées à la libération prolongée
WO2013132208A1 (fr) *	2012-03-05	2013-09-12	Cipla Limited	Combinaisons pharmaceutiques antirétrovirales comprenant de la lamivudine, du festinavir et de la névirapine
CN104523630B (zh) *	2015-01-22	2017-08-25	山东新时代药业有限公司	一种奈韦拉平片剂
EP3153157A1 (fr)	2015-10-09	2017-04-12	Teva Pharmaceutical Works Private Limited Company	Composition pharmaceutique à libération prolongée de névirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5366972A (en)	1989-04-20	1994-11-22	Boehringer Ingelheim Pharmaceuticals, Inc.	5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en)	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
CA2030056C (fr)	1989-11-17	1995-10-17	Karl D. Hargrave	5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines et leur utilisation pour la prevention ou le traitement de l'infection par le hiv
US5419917A (en) *	1994-02-14	1995-05-30	Andrx Pharmaceuticals, Inc.	Controlled release hydrogel formulation
US6514530B2 (en) *	1997-09-09	2003-02-04	Alza Corporation	Dosage form comprising means for changing drug delivery shape
ES2172944T3 (es)	1997-12-05	2002-10-01	Alza Corp	Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.
MXPA01006108A (es)	1998-12-17	2002-09-18	Alza Corp	Conversion de capsulas de gelatina rellenas de liquido en sistemas de liberacion controlada mediante multiples recubrimientos.
EP1169024B1 (fr) *	1999-03-31	2005-12-21	Janssen Pharmaceutica N.V.	Amidon pregelatinise dans une formulation a liberation regulee
MXPA02003182A (es) *	1999-09-24	2002-09-30	Janssen Pharmaceutica Nv	Composiciones antivirales.
DE60019334T2 (de)	1999-12-09	2005-09-08	Alza Corp., Mountain View	Antivirale arznei
US6541014B2 (en)	2000-10-13	2003-04-01	Advancis Pharmaceutical Corp.	Antiviral product, use and formulation thereof
WO2002092095A1 (fr)	2001-05-11	2002-11-21	Boehringer Ingelheim International Gmbh	Utilisation de nevirapine pour traiter ou prevenir des pathologies lipidiques chez des patients presentant une infection par vih resistante a la nevirapine
US20030050620A1 (en)	2001-09-07	2003-03-13	Isa Odidi	Combinatorial type controlled release drug delivery device
AU2003287666A1 (en)	2002-11-13	2004-06-03	Control Delivery Systems, Inc.	Systemic delivery of antiviral agents
CA2529852A1 (fr)	2003-06-20	2004-12-29	Viral Genomix, Inc.	Compositions et procedes de traitement du vih
CN1863512A (zh)	2003-10-01	2006-11-15	鲁宾有限公司	控释药物组合物及其制备方法
NZ581461A (en)	2003-11-13	2011-04-29	Psivida Inc	Injectable sustained release delivery devices
KR101284361B1 (ko) *	2004-09-02	2013-07-15	얀센 파마슈티카 엔.브이.	4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
WO2006114709A1 (fr) *	2005-04-25	2006-11-02	Aurobindo Pharma Limited	Compositions pharmaceutiques d'antiretroviraux
JP2009500318A (ja)	2005-06-29	2009-01-08	パナセアバイオテックリミテッド	新規な徐放性医薬組成物とその製法
US9198862B2 (en)	2005-07-22	2015-12-01	Rubicon Research Private Limited	Dispersible tablet composition
FR2891459B1 (fr)	2005-09-30	2007-12-28	Flamel Technologies Sa	Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007047371A2 (fr) *	2005-10-14	2007-04-26	Microdose Technologies, Inc.	Conditionnement pharmaceutique d'une combinaison posologique orale
ES2574836T3 (es)	2007-06-08	2016-06-22	Boehringer Ingelheim International Gmbh	Formulación de liberación prolongada de nevirapina

2008
- 2008-06-04 ES ES08756672.5T patent/ES2574836T3/es active Active
- 2008-06-04 KR KR1020097016610A patent/KR101017862B1/ko active Active
- 2008-06-04 UA UAA200908230A patent/UA97971C2/ru unknown
- 2008-06-04 CN CN2008800193577A patent/CN101784263B/zh active Active
- 2008-06-04 HU HUE08756672A patent/HUE028598T2/en unknown
- 2008-06-04 DK DK08756672.5T patent/DK2155169T3/en active
- 2008-06-04 CA CA2687491A patent/CA2687491C/fr active Active
- 2008-06-04 MX MX2009007764A patent/MX2009007764A/es active IP Right Grant
- 2008-06-04 PL PL08756672.5T patent/PL2155169T3/pl unknown
- 2008-06-04 WO PCT/US2008/065705 patent/WO2008154234A2/fr active Application Filing
- 2008-06-04 US US12/523,226 patent/US8460704B2/en active Active
- 2008-06-04 EA EA200900958A patent/EA018377B1/ru not_active IP Right Cessation
- 2008-06-04 AU AU2008262031A patent/AU2008262031B2/en not_active Ceased
- 2008-06-04 EP EP08756672.5A patent/EP2155169B1/fr not_active Revoked
- 2008-06-04 BR BRPI0811732-2A2A patent/BRPI0811732A2/pt not_active IP Right Cessation
- 2008-06-04 NZ NZ578664A patent/NZ578664A/en not_active IP Right Cessation
- 2008-06-04 JP JP2009552940A patent/JP5417662B2/ja active Active
- 2008-06-06 CL CL2008001678A patent/CL2008001678A1/es unknown
- 2008-06-06 PE PE2008000969A patent/PE20090371A1/es not_active Application Discontinuation
- 2008-06-06 UY UY31128A patent/UY31128A1/es not_active Application Discontinuation
- 2008-06-06 TW TW097121294A patent/TWI419716B/zh active
- 2008-06-06 AR ARP080102446A patent/AR066924A1/es unknown
- 2008-06-06 PE PE2013000070A patent/PE20131035A1/es not_active Application Discontinuation
2009
- 2009-07-15 ZA ZA200904939A patent/ZA200904939B/xx unknown
- 2009-07-16 IL IL199924A patent/IL199924A0/en unknown
- 2009-07-21 CO CO09075419A patent/CO6150128A2/es unknown
- 2009-08-05 EC EC2009009561A patent/ECSP099561A/es unknown
- 2009-12-04 TN TNP2009000510A patent/TN2009000510A1/fr unknown
- 2009-12-07 MA MA32400A patent/MA31430B1/fr unknown

Also Published As

Publication number	Publication date
JP2010520891A (ja)	2010-06-17
PL2155169T3 (pl)	2016-09-30
US8460704B2 (en)	2013-06-11
ZA200904939B (en)	2010-04-28
MA31430B1 (fr)	2010-06-01
PE20090371A1 (es)	2009-04-24
UA97971C2 (ru)	2012-04-10
WO2008154234A2 (fr)	2008-12-18
CA2687491A1 (fr)	2008-12-18
MX2009007764A (es)	2009-09-10
KR101017862B1 (ko)	2011-03-04
CA2687491C (fr)	2011-09-20
UY31128A1 (es)	2009-01-30
IL199924A0 (en)	2010-04-15
CN101784263A (zh)	2010-07-21
AU2008262031B2 (en)	2011-08-25
AR066924A1 (es)	2009-09-23
US20100278918A1 (en)	2010-11-04
JP5417662B2 (ja)	2014-02-19
CN101784263B (zh)	2012-11-07
EP2155169B1 (fr)	2016-03-23
WO2008154234A3 (fr)	2010-01-21
EA200900958A1 (ru)	2010-04-30
ES2574836T3 (es)	2016-06-22
DK2155169T3 (en)	2016-06-13
NZ578664A (en)	2011-11-25
TWI419716B (zh)	2013-12-21
PE20131035A1 (es)	2013-10-01
CL2008001678A1 (es)	2009-09-11
BRPI0811732A2 (pt)	2014-11-18
HK1145806A1 (en)	2011-05-06
AU2008262031A1 (en)	2008-12-18
KR20100020447A (ko)	2010-02-22
EP2155169A2 (fr)	2010-02-24
TW200916127A (en)	2009-04-16
CO6150128A2 (es)	2010-04-20
ECSP099561A (es)	2009-09-29
WO2008154234A9 (fr)	2009-11-26
HUE028598T2 (en)	2016-12-28
EA018377B1 (ru)	2013-07-30

Publication	Publication Date	Title
JOP20180102A1 (ar)	2019-01-30	مركب صيدلاني
TN2009000510A1 (en)	2011-03-31	Extended release formulation of nevirapine
MX2011007267A (es)	2011-08-15	Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina.
MX2012007098A (es)	2012-07-20	Derivados fenolicos y su uso farmaceutico o cosmetico.
PH12012501346A1 (en)	2012-12-17	Heteroaryl compounds and uses thereof
EA201101118A1 (ru)	2012-03-30	Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
MX2012007161A (es)	2012-07-03	Derivados fenolicos y su uso farmaceutico o cosmetico.
IL224288A (en)	2015-02-26	Derivatives of converted pyrazolamide, pharmaceutical preparations containing them and their use
MX2011014019A (es)	2012-02-22	Derivados de diazahomoadamantano y sus metodos de uso.
MY153915A (en)	2015-04-15	Organic compounds
SI2373681T1 (sl)	2017-05-31	Farmacevtski sestavki albiglutida
PL2079446T3 (pl)	2012-04-30	Preparat paliperidonu o przedłużonym uwalnianiu
EP2129672A4 (fr)	2009-12-09	Dérivés ester et carbamate d'azaadamantane et leurs procédés d'utilisation
WO2009115084A3 (fr)	2010-04-08	Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
IN2012DN03404A (fr)	2015-10-23
MX2010008852A (es)	2010-09-24	Formulaciones de flibanserina.
ZA201102652B (en)	2012-01-25	Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormane (gnrh) as immunogen
MX2009010176A (es)	2009-10-12	Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
EP2296687A4 (fr)	2012-12-26	Compositions pharmaceutiques de conjugués somatostatine-dopamine
MY165088A (en)	2018-02-28	Pharmaceutical compositions comprising alisporivir
ZA201101053B (en)	2012-07-25	Pharmaceutical compositions of samatotrophic hormones
AP2012006119A0 (en)	2012-02-29	Pharmaceutical composition of isoniazid.
MX2012008253A (es)	2012-08-15	Uso farmaceutico de compuestos multiciclicos como agentes anti-sindrome de inmunodeficiencia adquirida.
EP2568810A4 (fr)	2013-12-04	Compositions de darunavir
MX2012007097A (es)	2012-07-20	Derivados fenolicos y su uso farmaceutico o cosmetico.